Search for a trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to
3a or R/R Marginal Zone Lymphoma

This study has been transitioned to CTIS with ID 2023-504684-16-00 check the CTIS register for the current data. This study compares the efficacy of tafasitamab + lenalidomide + rituximab to the efficacy of placebo + lenalidomide + rituximab in…